Replies to post #508155 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Very good stuff. Thanks.

NWBO is about to fix Nature’s conclusion here imo.

August 23

In sum, these data suggest that autologous tumors are better sources of antigens and that DCs are more effective antigen presenters than lymphoma cells themselves. Overall, anonymous antigen ex vivo vaccines are promising for their greater potential to present the full spectrum of tumor antigens as compared to predefined antigen vaccines and their demonstrable efficacy in inducing systemic tumor regressions100. Still, these are limited by the resource commitment of creating personalized, GMP-compliant products for each patient, which has slowed their development.** — Nature

**Objects in rear view mirror are closer than they appear.

[sukus]

DCVax-L was mentioned. Awesome. Thanks.

Autologous tumor lysate-based approaches may be preferable to shared antigens, as suggested by a study comparing parallel cohorts of autologous GBM tumor lysate-pulsed DCs versus GBM shared antigen-pulsed DCs98. This analysis found a correlation between decreased regulatory T cell (Treg) ratios and OS, including median survivals of 34 months versus 15 months favoring the autologous approach (DCVax-L), prompting an ongoing phase III trial (NCT00045968).

[hoffmann6383]

Thanks!